# NCT02324452 (NCT02324452)

> Safety, Feasibility and Cost-effectiveness of Genotype-directed Individualized Dosing of Fluoropyrimidines

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02324452
- Phase: NA
- Status: COMPLETED
- Sponsor: The Netherlands Cancer Institute
- Conditions: Neoplasms
- Interventions: Fluoropyrimidine (capecitabine or 5-fluorouracil)
- Enrollment: 1103
- Primary outcome: Safety: incidence of severe treatment-related toxicity (CTC grade 3 to 5)

## Indexed commentary on NCT02324452 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nct02324452